The Alzheimer's Association International Conference (AAIC 2025) is the premier global forum for groundbreaking research in Alzheimer's disease (AD) and dementia. As a leader in preclinical models, GemPharmatech is proud to showcase our advanced AD mouse models at this year's conference. Join us to explore how our innovative tools can accelerate your research and drive the next wave of therapeutic breakthroughs.

Why Focus on Alzheimer's Research?

Alzheimer's disease affects over 50 million people worldwide, with numbers expected to triple by 2050. Despite decades of research, effective disease-modifying treatments remain elusive. The urgency to understand the roles of amyloid-beta plaques, tau tangles, and neuroinflammation has never been greater, and the dissemination of data and ensuing scientific dialogues taking place at AAIC will help shape the future of Alzheimer's research.

GemPharmatech will present our latest transgenic AD mouse models, designed to replicate the complex pathology of human Alzheimer's. These models enable researchers to:

• Study disease mechanisms with high clinical relevance.

• Screen potential therapeutic agents and evaluate their safety.

• Accelerate preclinical trials with reproducible, high-fidelity data.

Spotlight on GemPharmatech's AD Mouse Models

Our models are engineered to mirror key aspects of AD progression, offering researchers unparalleled tools for drug discovery and mechanistic studies.

1. FAD^3T Mouse Model

Key Features:

• Changes in blood diagnostic biomarkers and elevated phosphorylated Tau levels are detectable at 1 month of age.

• Aβ plaque aggregation starts at 2 months.

• Female mice exhibit cognitive impairment at three months of age, with similar deficits appearing in males at four months.

Advantages and Applications:

• Comprehensive simulation of clinical patient manifestations, spanning from diagnostic features to pathological hallmarks of hyperphosphorylated tau protein and Aβ plaque aggregation, and associated behavioral changes.

2. FAD^4T Mouse Model

Key Features:

• Early-onset Aβ plaque aggregation (starting at 2 months).

• Accompanied by gliosis (2 months) and cognitive impairment (8 months).

Advantages and Applications:

• Ideal for comprehensive drug evaluation.

3. FAD^2T Mouse Model

Key Features:

• Aβ plaque aggregation starts at 4 months of age.

• Cognitive impairment starts at 8 months.

Advantages and Applications:

• Mild to moderate Aβ plaque aggregation and ideal for preventive intervention research.

Join Us at AAIC 2025!

Date: July 27-31, 2025

Location: Toronto, Canada

Visit the GemPharmatech Poster (#102567) to:

• Explore more information about our advanced AD models.

• Discuss collaboration opportunities with our scientists.

• Learn how our mouse models and preclinical services can power your next breakthrough.

Let's shape the future of Alzheimer's research together.

Contact Us Today: sales@gempharmatech.com

See You at AAIC 2025!